Cintirorgon

Cintirorgon
Clinical data
Other namesLYC-55716
Drug classRORγ agonist
Identifiers
  • 3-[(2S)-6-[3-(difluoromethoxy)-5-fluorophenyl]-4-[3-(trifluoromethyl)phenyl]sulfonyl-2,3-dihydro-1,4-benzoxazin-2-yl]-2,2-dimethylpropanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC27H23F6NO6S
Molar mass603.53 g·mol−1
3D model (JSmol)
  • CC(C)(C[C@H]1CN(C2=C(O1)C=CC(=C2)C3=CC(=CC(=C3)F)OC(F)F)S(=O)(=O)C4=CC=CC(=C4)C(F)(F)F)C(=O)O
  • InChI=1S/C27H23F6NO6S/c1-26(2,24(35)36)13-20-14-34(41(37,38)21-5-3-4-17(11-21)27(31,32)33)22-10-15(6-7-23(22)39-20)16-8-18(28)12-19(9-16)40-25(29)30/h3-12,20,25H,13-14H2,1-2H3,(H,35,36)/t20-/m0/s1
  • Key:GULSIMHVQYBADX-FQEVSTJZSA-N

Cintirorgon (LYC-55716) is a drug which acts as a selective agonist of the receptor RAR-related orphan receptor gamma (RORγ). It was developed for the treatment of certain forms of cancer and is in early stage human clinical trials.